RT Journal Article SR Electronic T1 Outcomes of loop electrosurgical excision procedure for cervical neoplasia in human immunodeficiency virus–infected women JF International Journal of Gynecologic Cancer JO Int J Gynecol Cancer FD BMJ Publishing Group Ltd SP 1082 OP 1088 DO 10.1136/ijgc-00009577-200605000-00021 VO 16 IS 3 A1 C. Kietpeerakool A1 J. Srisomboon A1 P. Suprasert A1 C. Phongnarisorn A1 K. Charoenkwan A1 C. Cheewakriangkrai A1 S. Siriaree A1 C. Tantipalakorn A1 A. Pantusart YR 2006 UL http://ijgc.bmj.com/content/16/3/1082.abstract AB The objective of this study was to evaluate the treatment outcomes and complications in human immunodeficiency virus (HIV)–infected women undergoing loop electrosurgical excision procedure (LEEP) for cervical neoplasia. The medical record of 60 evaluable HIV-infected women who had abnormal Papanicolaou (Pap) smear and underwent LEEP following colposcopy at Chiang Mai University Hospital between May 1998 and June 2004 was reviewed. Thirty-one (51.7%) had associated genital infection at screening. Twenty-five (41.7%) had opportunistic infection, but only 18 (30.0%) were treated with antiretroviral therapy. The most common abnormal Pap smear was high-grade squamous intraepithelial lesion (46.7%), followed by low-grade squamous intraepithelial lesion (40.0%). Forty (66.7%) women had clear surgical margins after LEEP. Only one (1.7%) woman had severe intraoperative hemorrhage. Early and late postoperative hemorrhage were noted in three (5%) women of each period. Localized infection of the cervix was detected in seven (11.7%) women. Two (3.3%) women developed cervical stenosis at 6 months after LEEP. There was no significant difference in overall complications between HIV-infected women and the control group (P = 0.24). Among 60 HIV-infected women, no statistical difference in the rate of margins involvement (P = 1.00) and complications (P = 0.85) could be demonstrated between HIV-infected women who received antiretroviral therapy and those who did not. Disease-free rate at 6 and 12 months were 97.1% and 88%, respectively. These data demonstrated that LEEP appears to be safe and effective in HIV-infected women.